Last reviewed · How we verify
NCT03239158
Bioinformation Therapy for Liver Cancer
Phase 2, PHASE3 trial testing Cancer ablation in Liver, Cancer of, Non-Resectable in 120 participants. Completed in 2 September 2018.
2 September 2018
Quick facts
| Lead sponsor | Fuda Cancer Hospital, Guangzhou |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 2 September 2017 |
| Primary completion | 2 September 2018 |
| Estimated completion | 2 September 2018 |
| Sites | 1 location across China |
Drugs / interventions tested
- Cancer ablation
- Life information rehabilitation therapy — full drug profile →
Conditions studied
- Liver, Cancer of, Non-Resectable — all drugs for Liver, Cancer of, Non-Resectable →
Sponsor
Fuda Cancer Hospital, Guangzhou
Who can join
Adults 30 to 80, any sex, with Liver, Cancer of, Non-Resectable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable liver cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03239158
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cancer ablation
Trials testing the same drug.
- NCT03350490 — Bioinformation Therapy for Intestinal Cancer · Phase 2, PHASE3 · completed
- NCT03350477 — Bioinformation Therapy for Gastric Cancer · Phase 2, PHASE3 · completed
- NCT03240224 — Bioinformation Therapy for Breast Cancer · Phase 2, PHASE3 · completed
- NCT03239171 — Bioinformation Therapy for Lung Cancer · Phase 2, PHASE3 · completed
- NCT03239184 — Bioinformation Therapy for Pancreatic Cancer · Phase 2, PHASE3 · completed
Other Fuda Cancer Hospital, Guangzhou trials
Trials by the same sponsor.
- NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
- NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
- NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
- NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
- NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03239158 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
- Last refreshed: 25 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03239158.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing